[68Ga] Ga NNS309
Alternative Names: [68Ga]Ga-NNS309Latest Information Update: 11 Oct 2024
At a glance
- Originator Novartis Pharmaceuticals
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Adenocarcinoma; Breast cancer; Colorectal cancer; Non-small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 01 Oct 2024 Phase-I clinical trials in Adenocarcinoma (Diagnosis) in Israel (Parenteral) (NCT06562192) (EudraCT2023-510356-23)
- 01 Oct 2024 Phase-I clinical trials in Breast cancer (Diagnosis) in Israel (Parenteral) (NCT06562192) (EudraCT2023-510356-23)
- 01 Oct 2024 Phase-I clinical trials in Colorectal cancer (Diagnosis) in Israel (Parenteral) (NCT06562192) (EudraCT2023-510356-23)